Cat. No. | Product name | CAS No. |
DC11367 |
PF-04447943
Featured
PF-04447943 is a brain-permeable phosphodiesterase (PDE) inhibitor that is selective for PDE9A (IC50 = 12 nM) over other PDEs (IC50s = >940 nM) in enzymatic assays of second messenger hydrolysis. |
1082744-20-4 |
DC9915 |
PF04995274,PF 04995274
Featured
PF-04995274 is a 5-HT4 receptor partial agonist. It thought to act centrally as a pro-cognitive agent that being developed for the treatment of Alzheimer's disease (AD). |
1331782-27-4 |
DCAPI1435 |
Rivastigmine tartrate
Rivastigmine hydrogen tartrate is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and Parkinson's disease. |
129101-54-8 |
DC7496 |
Semagacestat
Featured
Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM. |
425386-60-3 |
DC9842 |
T0901317
Featured
T0901317 is a potent, high affinity liver X receptor (LXR) agonist (EC50 ~ 50 nM, Kd values are 7 and 22 nM for LXR-α and LXR-β respectively). |
293754-55-9 |
DC11208 |
TAK-071
Featured
TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM. |
1820812-16-5 |
DC10217 |
TRx0237 (LMTX) mesylate
Featured
TRx 0237 (LMTX™) mesylate is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. |
1236208-20-0 |
DC4173 |
VX-745
Featured
VX-745 is a potent and selective inhibitor of p38α MAPK and p38β MAPK with IC50 of 10 nM and 220 nM, respectively. |
209410-46-8 |
DC9498 |
Xanomeline (oxalate)
Xanomeline(LY246708) is a selective M1 muscarinic receptor agonist. |
141064-23-5 |